FDA Guidance Documents
FDA (Food and Drug Administration)
List of FDA Clinical Trials Guidance Documents
Continuing Review
- Continuing Review after Clinical Investigation Approval
- IRB Continuing Review After Clinical Investigation Approval
Development and Approval Process -- IDE
- Draft Guidance FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations
- Factors to Consider when Making Risk Benefit Determinations for IDEs
- IDE Guidance
- IDE Policies and Procedures
- Significant Risk and Nonsignificant Risk Medical Device Studies
Development and Approval Process -- IND
- Content and Format of IND Application for Phase 1
- Final Rule: IND Safety Reporting
- How to Put Together an Application (pdf)
- Individual Patient IND under Expanded Access for Non-emergency or Emergency Use
- IND Application Overview
- IND Applications for Clinical Treatment with Investigational Drugs in Emergency Situations
- Draft Guidance IND Applications Prepared and Submitted by Sponsor Investigators
- IND Meetings for Human Drugs and Biologics
- Investigator-Initiated Investigational New Drug (IND) Applications
- "Off Label" and Investigational Use of Marketed Drugs, Biologics and Medical Devices
- Overview of the IND Process CBER 101 -- An Introduction to CBER (pdf)
- Safety Reporting Requirements for INDs and BA/BE Studies
- Safety Reporting Requirements for INDs and BA/BE Studies - Small Entity Compliance Guide
- Submitting an IND -- what you need to know (PowerPoint)
- Submitting IND Applications
Expanded Access (21 CFR parts 312 and 316)
Form Guidance
Frequently Asked Questions (FAQs)
- FAQ about Medical Devices
- FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND, Frequently Asked Questions
Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards
Guidance for Industry
- Chemistry, Manufacturing, and Controls (CMC) for Phase 2 and 3 Studies
- Collection of Race and Ethnicity Data in Clinical Trials
- Data Retention when Subjects Withdraw from FDA-Regulated Clinical Trials
- Drug Master Files (pdf)
- E2F Development Safety Update Report (DSUR)
- E6 Good Clinical Practice: Consolidated Guidance
- E14 Clinical Evaluation of QT/Qtc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
- Exemptions for Studies of Lawfully Marketed Drug or Biological Products
- FDA Definition of Disease Prevalence for Therapies Qualifying under the Orphan Drug Act
Guidance for the Public, FDA Advisory Committee Members, and FDA Staff
Informed Consent Elements
- Elements of Informed Consent
- FDA New Requirements Informed Consent
- Questions and Answers on Informed Consent Elements, 21 CFR § 50.35 (c)
Inspections and Monitoring
- Compliance Program Guidance Manual
- FDA Inspections of Clinical Investigators
- Draft Guidance Oversight of Clinical Investigations -- A Risk-Based Approach to Monitoring
Investigator Responsibilities